

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE SHARES OF THE COMPANY
IN THE HONG KONG STOCK CONNECT**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, with effect from 7 September 2026, the shares of the Company (the “**Shares**”) are included in the list of shares of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, qualified investors in Chinese Mainland can directly invest in the Shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 7 September 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.